Researchers at The University of Queensland (UQ) have developed a diagnostic device, the Phenotype Analyzer Chip, designed to monitor glioblastoma, an aggressive form of brain cancer, and potentially aid in the detection of other neurological conditions. The non-invasive blood test aims to provide rapid and precise information on disease progression and treatment effectiveness, potentially reducing the reliance on invasive procedures.
The non-invasive blood test aims to provide rapid and precise information on disease progression and treatment effectiveness, potentially reducing the reliance on invasive procedures.
Development and Purpose
The Phenotype Analyzer Chip was developed by Dr. Richard Lobb and Dr. Zhen Zhang from UQ’s Australian Institute for Bioengineering and Nanotechnology, in collaboration with ARC Laureate Professor Matt Trau. The device is designed to assess how glioblastoma responds to treatment, offering a non-invasive method for gathering brain health data. Its stated purpose includes improving brain cancer monitoring, potentially enhancing patient outcomes, and altering treatment approaches.
How the Device Works
The chip operates by analyzing small biological particles, known as extracellular vesicles, found in a patient's bloodstream. These vesicles, described as "messenger cells," carry information about cellular activity and originate from glioblastoma tumor tissue. They are capable of crossing the blood-brain barrier, carrying disease-related information into the blood. The hypersensitive device detects and analyzes these particles from blood samples, providing insights into biological processes within the brain and the effectiveness of treatments. The device's hypersensitivity is attributed to unique bionanotechnology innovations from the Trau lab.
Glioblastoma: Context and Current Monitoring Challenges
Glioblastoma is reported as the most common and aggressive form of brain cancer in Australia. Annually, the country records over 2,000 new diagnoses and approximately 1,640 deaths attributed to the disease. Its delicate location, aggressive growth, and inherent difficulties in monitoring treatment progress contribute to its high mortality rate.
Current diagnostic methods, such as MRI scans and biopsies, are essential for initial diagnosis. However, these methods present limitations for ongoing treatment monitoring.
MRI scans can sometimes be ambiguous, making it difficult to differentiate between tumor growth and brain reactions to therapy, which can necessitate further invasive brain biopsies.
Additionally, MRI imaging may only detect therapeutic progress in later stages, potentially delaying adjustments to treatment.
Advantages and Clinical Impact
The Phenotype Analyzer Chip aims to address these challenges by providing early and precise information about the disease. This data could allow for more informed and timely adjustments to treatment pathways without requiring invasive procedures.
The non-invasive nature of the blood test is anticipated to be particularly beneficial for patients in regional areas who often face travel requirements for advanced medical care.
Validation and Future Applications
The device has undergone validation in clinical settings, involving over 40 brain cancer patients. It is currently slated for implementation in broader clinical trials. Beyond glioblastoma, the technology shows potential for monitoring other neurological disorders. Researchers suggest it could be adapted for conditions such as Alzheimer’s, Parkinson’s, Motor Neurone Disease (MND), and depression, by analyzing brain-specific biomarkers and detecting neuroinflammation through extracellular vesicles in blood samples.
Research Publication and Collaborations
The research findings were published in the scientific journal Science Advances. The development of the Phenotype Analyzer Chip involved a collaborative effort with researchers from the Mark Hughes Foundation Centre for Brain Cancer Research at the University of Newcastle. Patient samples for validation were sourced from the MHF Brain Cancer Biobank, and the project received funding support from the Mark Hughes Foundation.